Nektar Therapeutics - Common Stock (NQ:NKTR)

37.92 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial ↗

October 01, 2026

Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to...

Via MarketBeat

Nektar (NKTR) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.

Via The Motley Fool

Topics Earnings

Nektar Therapeutics Q2 Earnings Call Highlights ↗

August 13, 2026

Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing...

Via MarketBeat

Topics Earnings

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower ↗

May 07, 2026

Via Chartmill

Topics Earnings

Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call ↗

August 13, 2026

Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For...

Via Benzinga

What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year ↗

June 24, 2026

This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗

May 23, 2026

Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.

Via The Motley Fool

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗

May 23, 2026

GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.

Via The Motley Fool

Topics Artificial Intelligence

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

Nektar Therapeutics Q1 Earnings Call Highlights ↗

May 08, 2026

Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026...

Via MarketBeat

Topics Earnings

Nektar (NKTR) Q1 2026 Earnings Transcript ↗

May 07, 2026

Nektar (NKTR) Q1 2026 Earnings Transcript

Via The Motley Fool

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR

May 05, 2026

From Pomerantz LLP

Via GlobeNewswire

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th

May 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

May 04, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

May 04, 2026

From Schall Law

Via GlobeNewswire

NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR

April 30, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 30, 2026

From Schall Law

Via GlobeNewswire

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

April 30, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR

April 28, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

April 28, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

April 27, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights

April 27, 2026

From Rosen Law Firm

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 27, 2026

From Schall Law

Via GlobeNewswire

Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights

April 23, 2026

From Robbins LLP

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 23, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)

April 23, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

April 21, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

April 21, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Why Nektar Therapeutics Stock Rocked it Today ↗

April 20, 2026

The biotech reported solid results from its investigational immunology drug in the treatment of a hair-loss disorder.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.